[Translation] A multicenter, randomized, double-blind, placebo-combined basic treatment, parallel-controlled phase II clinical trial of recombinant human nerve growth factor for injection in patients with non-arteritic anterior ischemic optic neuropathy
主要目的:在I期临床试验的基础上,在非动脉炎性前部缺血性视神经病变患者中进一步探讨其有效剂量,为III期临床试验安全性和有效性提供依据; 次要目的:评价注射用重组人神经生长因子在非动脉炎性前部缺血性视神经病变患者中的安全性。
[Translation] Main purpose: Based on the Phase I clinical trial, further explore its effective dose in patients with non-arteritic anterior ischemic optic neuropathy to provide a basis for the safety and efficacy of the Phase III clinical trial; Secondary purpose: Evaluate the safety of recombinant human nerve growth factor for injection in patients with non-arteritic anterior ischemic optic neuropathy.